RE: St George's Day19 Apr 2020 12:18
Hi WBernard, happy to be engaged in this debate. Have been on this BB for years and only registered today for this company. IMHO, the sensitivity is probably the biggest challenge faced by AVCT, based on my research of its current market competitors. The Canadian company Sona Nanotech and US company Mammoth BioSciences. Sona has competed the test and now in validation stage, so the sensitivity results remain unknown. Mommoth has the CRISPR test running but evidence shows that the test is not sensitive enough when the density of the virus is low. Given our AVCT Zika Affimer POC test hasn't been validated clinically, I would say the sensitivity to low amount of virus might be the biggest challenge, which may lead to a considerately large amount of false negatives. But as long as it can pass the threshold, the low cost and efficiency will outweigh the labor-intensive PCR test.
Br